Navigation Links
MD Anderson Becomes a GeneGo Center of Excellence Using MetaCore for Oncology Research
Date:9/2/2008

ST. JOSEPH, Mich., Sept. 2 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that MD Anderson has become a certified GeneGo Center of Excellence. MD Anderson researchers will have institution-wide access to GeneGo's MetaCore data analysis suite, training and advanced support. MD Anderson specializes in cancer treatment and research and is well known for its advanced clinical trials programs. MetaCore will be used throughout many research programs both as a central data repository, management and collaboration platform for clinical OMICs data and as an integrative pathway analysis suite.

Mary E. Edgerton, a pathologist performing cancer research at MD Anderson and a long-term client, says "I have been using MetaCore for many years in my research into pathways and networks that control aggressive behavior in cancers. I am currently using it to infer networks from analysis of gene expression array data for pathways in lung, brain, and breast cancer. I also use the curated pathways to formulate mathematical models of molecular networks that predict tumor behavior using multiscale modeling. Not only do I find the product to be very useful, but I also appreciate the responsiveness of the staff at GeneGo to my technical questions and suggestions. "

"MD Anderson is renowned for their pioneering work in oncology. I have known some of the MD's there for a while and I admire their dedication to their patients and to working hard to find cures," said Julie Bryant, GeneGo's VP of Business development. "We are proud to have them as an institution customer and a Center of Excellence. We have a large development program in the area of cancer system biology tools supported by NCI and we are glad to see this work appreciated by some of the best oncology professionals in the world working at MD Anderson."

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.0(TM), assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.0(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore.

For more information, please visit the company's web site at http://www.genego.com.


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. M. D. Anderson Automates Laboratory Workflow with Stone Bond Technologies : EE-LIMS™ from Stone Bond Technologies Will Document Activities within the Laboratory Workflow at the siRNA Facility, Increasing Throughput, While Reducing Risks
2. DermTech Names Herbert A. Fritsche, Ph.D., Chief of Clinical Chemistry at M.D. Anderson Cancer Center to Companys Scientific Advisory Board
3. Truman Medical Centers Becomes One of the First Hospitals in the U.S. To Install the Worlds First Adaptive 128-slice CT Scanner
4. University of Miami Miller School of Medicine Becomes a GeneGo Center of Excellence
5. 18-Month Extension of Reimbursement Rates for Radioimmunotherapies Becomes Law After Congressional Override of Presidential Veto
6. Yale Keck Microarray Center Becomes a GeneGo Center of Excellence
7. Medical Ventures Becomes Neovasc with Two Corporate Acquisitions and $8.3 Million Financing
8. SURGEX(TM) Becomes the Official Sports Nutrition Drink of Former NBA Player Dee Brown and his Edge Basketball Training Facility
9. Bioheart Founder, Howard J. Leonhardt, Becomes Chairman of the Board of Directors
10. REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
11. Prof. Michel Klein Becomes Chief Scientific Officer at AMVAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... Do More with OHAUS , With the launch ... supplier in the weighing industry, to extending its expertise across the entire laboratory to ... hybridizations and more, allowing for its customers to 'Do More' in the ...
(Date:6/19/2017)... ... 19, 2017 , ... EDETEK, Inc., a clinical technology company ... launching two new additions of its award-winning cloud-based platform CONFORM™: Information Hub and ... 2017 Annual Meeting in Chicago, IL, June 19-22, 2017. , “Modern clinical trials ...
(Date:6/16/2017)... ... June 16, 2017 , ... ... and commercialization, has just announced two more sessions of its “From the Helm” ... focus on the world of online templates for design control exercises. Led by ...
(Date:6/15/2017)... ... June 15, 2017 , ... New resistant soybean ... options for managing Palmer amaranth and other broadleaf weeds resistant to glyphosate. But ... necessary. Auxin herbicides are known to drift and to cause harm to sensitive, ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition ... their offering. ... tracking market to grow at a CAGR of 30.37% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
Breaking Biology News(10 mins):